November 11, 2024—iVascular announced the initiation of OPAL, a first-in-human study of Amber, the company’s embolic liquid ...

CVRx, Inc. announced recently that the Centers for Medicare and Medicaid Services (CMS) assigned the company’s Barostim p ...

Medtronic and Recor Medical, Inc. (and its parent company, Otsuka Medical Devices Co., Ltd.) separately and independently ...

In the LIFE-BTK trial, several initiatives were implemented to facilitate enrollment of diverse populations, ensuring that pati ...

A nationwide retrospective study evaluated health care resource utilization and outcomes among patients with intermediate-risk ...

Data from the STRIDE study suggest that race, not sex, is associated with outcomes in acute limb ischemia (ALI) treated with me ...

Akura Medical, a Shifamed portfolio company focused on venous thromboembolism care, announced recently that the FDA has approve ...

A study assessed the effects of intravascular volume expansion on deep pelvic vein size using the 200-150-125 rule for the ...

DEEPER OUS is a prospective, nonrandomized, multicenter, single-arm trial taking place in New Zealand, Germany, and Switzerland ...

Secondary outcomes through 6 months were reported from the VenaSeal Spectrum Surgical Stripping study, a randomized ...

Two-year outcomes from the PROMISE II trial assessed transcatheter arterialization of the deep veins (TADV) using the LimFlow S ...

Investigators from the LIFE-BTK randomized controlled trial evaluating the use of the Drug-Eluting Resorbable Scaffold (Abbott) ...